Halozyme Therapeutics

Halozyme is a royalty machine masquerading as a biotech. The entire enterprise sits on one molecule — recombinant human hyaluronidase (rHuPH20), branded ENHANZE — that lets a drug developer convert any monoclonal antibody from a 90-minute IV infusion into a 5-minute subcutaneous injection. There is no other clinically validated platform that does this at FDA-approval scale, and the moat is composition-of-matter + manufacturing process patents protecting the molecule through 2027 in the US and 2029 in EU/Japan.

The royalty book through 2026 is dominated by four partner products: DARZALEX SC (J&J, multiple myeloma — USD 12.4 B partner sales 2025, Halozyme keeps ~5%), PHESGO (Roche, HER2+ breast — USD 2.1 B), VYVGART Hytrulo (Argenx, generalized myasthenia gravis — USD 1.8 B and growing 60% YoY), and Tecentriq SC (Roche — USD 480 M ramp). Total partner-product revenue exits 2025 at roughly USD 17 B; Halozyme's royalty + collaboration revenue base is USD 1.03 B trailing.

The misread the market has not fully digested: every IV antibody in oncology and immunology is now under conversion pressure — patients prefer 5-minute clinic visits, payers prefer outpatient billing codes. Bristol Myers' Opdivo SC (filed Q4/2025), Merck's Keytruda SC (Phase 3 readout Q3/2026), and AstraZeneca's Imfinzi SC are all on the Halozyme platform.

Institutional ownership shows a clear value-investor tilt. Wellington Management 9.8% (added through 2025), Vanguard 11.3%, BlackRock 8.7%. The conviction position is from Renaissance Technologies — net long since Q2/2024 with average cost basis around USD 45. Most notably: Stanley Druckenmiller's Duquesne disclosed a new 1.6 M-share position in the May 2026 13F (Q1/2026 filing), entering at USD 55-62. Druckenmiller does not chase mid-caps; this is a thesis trade.

Insider activity is dominated by one event. CEO Helen Torley sold USD 8.4 M of stock at USD 71-78 between January and April 2026 — but this was through a pre-set 10b5-1 plan filed in October 2025 to fund a foundation gift, not an opportunistic dump. CFO Nicole LaBrosse has bought USD 600 K in open-market purchases over the same period.

Short interest is elevated at 12.4% of float — mostly thesis shorts betting on the 2027 US ENHANZE patent expiry. The bull-side argument is that the manufacturing-process patents (separate, granted, valid through 2034) make biosimilar entry impractical.

The valuation looks extreme on the surface but cleans up fast. Trailing P/E 23.5x, forward P/E 6.8x — a five-handle forward multiple reflects consensus modeling of patent-cliff revenue decline in 2027-2028. The bull math: if process-patent defense holds and biosimilar entry is delayed to 2030+, FY28 EPS lands at USD 12+ (vs current trailing USD 2.8), making the 6.8x forward look like 5x on a real run-rate basis. EV/Sales forward 6.4x against royalty-pharma peer Royalty Pharma at 7.8x and Ionis at 9.1x. Analyst target USD 85 (+27% upside) is conservative; the bull case (process patents hold, Keytruda SC ramps as expected) gets to USD 130-150.

1. Q3 2026 Keytruda SC Phase 3 readout: Merck MK-3475A-D77 head-to-head SC vs IV pharmacokinetic non-inferiority — positive readout opens a USD 30B Keytruda IV base for SC conversion on ENHANZE
2. Late 2026 Opdivo SC FDA decision: BMS Opdivo SC PDUFA — second large oncology IV-to-SC conversion on ENHANZE platform; adds USD 60-90M annual royalty potential by 2028
3. Q1 2027 ENHANZE composition patent expiry decisions: USPTO + EPO process patent enforceability rulings expected through 2027; first biosimilar PH20 filings will start clarifying competitive timeline

Halozyme is the cleanest royalty-machine in mid-cap biotech right now, but the patent-cliff debate is genuine and the stock will not re-rate cleanly until late 2027 when biosimilar-PH20 timing is known. The asymmetry: if process patents force-block biosimilars to 2030+, the forward P/E re-rates from 6.8x to a peer 13-15x (~USD 130 share price). If a biosimilar lands in 2028, the next-three-year royalty decline puts the stock at USD 40-45. So the trade is essentially binary on the patent question, mid-2027 inflection. I would size 1.5-2% of equity with a stop at USD 52 — buying the asymmetry but not pretending to know which way the courts go. The Druckenmiller filing matters: he does not buy a 1.6 M-share position into binary biotech unless he believes the process-patent moat holds, and his information advantage on this specific question is meaningful.